Aequus Pharmaceuticals Inc. (CVE:AQS – Get Free Report) shares hit a new 52-week low during mid-day trading on Wednesday . The stock traded as low as C$0.01 and last traded at C$0.01, with a volume of 14000 shares changing hands. The stock had previously closed at C$0.01.
Aequus Pharmaceuticals Stock Performance
The firm’s fifty day moving average is C$0.01 and its 200-day moving average is C$0.01. The company has a current ratio of 0.07, a quick ratio of 0.46 and a debt-to-equity ratio of 138.88. The stock has a market capitalization of C$663,150.00, a PE ratio of -0.50 and a beta of -0.02.
About Aequus Pharmaceuticals
Aequus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease.
Further Reading
- Five stocks we like better than Aequus Pharmaceuticals
- 5 Top Rated Dividend Stocks to Consider
- Nebius Group: Market Overreaction or Real AI Disruption?
- How Can Investors Benefit From After-Hours Trading
- The Best Way to Invest in Gold Is…
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Why Nike Stock Could Be 2025’s Top Comeback Play
Receive News & Ratings for Aequus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aequus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
